Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema

Călugăru, Dan; Călugăru, Mihai

doi:10.1007/s00417-018-4126-2

Cited by 4 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the one hand, Sarda et al reported that the mean visual gain observed in their study was +10.1 ETDRS letters and reduction in CMT was 65.1 μ m after 5 aflibercept or ranibizumab intravitreal injections [ 27 ]. On the other hand, Călugăru et al demonstrated that the mean BCVA improved and CMT decreased significantly compared to the baseline values after anti-VEGF therapy in anatomic nonresponders and responders [ 28 ]. As in other studies, Vujosevic et al observed the significant improvement in BCVA with mean change of 13 ± 10 ETDRS letters after treatment.…”

Section: Discussionmentioning

confidence: 99%

“…We conducted a 12-month prospective study on DME patients who were treated with fixed-regimen intravitreal bevacizumab injections. Only treatment-naïve patients were included, and all of them received nine bevacizumab injections, while in many other studies, patients received fewer injections of anti-VEGF inhibitors [ 12 , 18 , 27 , 28 ]. In addition, both the number of injections and follow-up period and the number of assessed parameters were lower in other studies compared to our study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Response to 1-Year Fixed-Regimen Bevacizumab Therapy in Treatment-Naïve DME Patients: Assessment by OCT Angiography

Hunt

Teper

Wylęgała

et al. 2022

Journal of Diabetes Research

View full text Add to dashboard Cite

Purpose. To evaluate the effectiveness of intravitreal bevacizumab treatment in patients with diabetic macular edema (DME) by assessing retinal changes using optical coherence tomography angiography (OCT-A). Methods. This prospective study was performed in patients with treatment-naïve DME. The eyes of patients were imaged using a swept-source OCT system with a scan area of 6 × 6 mm. The DME patients with a central macular thickness (CMT) of ≥300 μm received nine bevacizumab injections within 12 months. The demographic, systemic, and ocular parameters, including the best-corrected visual acuity (BCVA), CMT, microaneurysm (MA) count, and foveal avascular zone (FAZ) area in both superficial capillary plexus (SCP) and deep capillary plexus (DCP), as well as vessel density in SCP, were assessed in the patients. In addition, the response (good or poor) of the DME eyes to bevacizumab treatment and the final visual acuity (BCVA of 75 letters) were analyzed. Results. Seventy-seven eyes of DME patients were subjected to the final analysis. Bevacizumab treatment reduced CMT from 425.06 μm (±77.15) to 350.25 μm (±82.04) and improved BCVA by about 8.61 letters (from 64.73 to 73.34) in the patients. The mean number of MAs in SCP decreased from 3.51 ± 2.07 to 2.31 ± 1.15 ( p < 0.001 ) and in DCP from 17.12 ± 11.56 to 12.21 ± 6.99 ( p < 0.001 ), whereas the area of FAZ increased in SCP from 328.22 ± 131.38 to 399.70 ± 156.98 ( p < 0.001 ) and in DCP from 571.13 ± 396.01 to 665.89 ± 412.77 ( p = 0.001 ). The final BCVA letter score and CMT were statistically significant in both poor and good responders, as well as in BCVA < 75 and BCVA ≥ 75 groups. Conclusion. The fixed-regimen intravitreal bevacizumab therapy was effective in treating DME. Apart from noninvasive visualization of microvascular damage, OCT-A showed limited usefulness in predicting treatment response. Although the study showed that the number of MAs was significantly reduced during treatment, which is an OCT-A predictor of a good response to bevacizumab treatment at a 12-month visit, commonly observed artifacts may reduce the usefulness of OCT-A.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Response to 1-Year Fixed-Regimen Bevacizumab Therapy in Treatment-Naïve DME Patients: Assessment by OCT Angiography

Hunt

Teper

Wylęgała

et al. 2022

Journal of Diabetes Research

View full text Add to dashboard Cite

show abstract

“…Therefore, addition of a non-specific anti-VEGF substance, e.g., intravitreal steroid injection, which inhibits the upregulation of VEGF and suppresses the expression of the whole inflammatory factors is mandatory. Otherwise, patients will be impeded to achieve maximal visual and anatomic benefits [ 51 - 58 ].…”

Section: The Persistent Dmementioning

confidence: 99%

Romanian ophthalmologists in the renowned ophthalmic journals worldwide

Călugăru¹,

Călugăru²

2018

rjo

Self Cite

View full text Add to dashboard Cite

The authors are discussing over 80 articles that they have published in the last 5 years in the renowned ophthalmic journals worldwide, which have approached, for the first time in the ophthalmic literature, the following 4 topics: the acute central/ hemicentral retinal vein occlusion, the therapeutic interventions in the fellow eye of patients with unilateral malignant glaucoma, the persistent diabetic macular edema, and the current researches in patients with neovascular age-related macular degeneration.

show abstract

Subfoveal choroidal thickness changes after intravitreal ranibizumab injections in different patterns of diabetic macular edema using a deep learning-based auto-segmentation

Wang

Cai

et al. 2021

Int Ophthalmol

View full text Add to dashboard Cite

Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema

Cited by 4 publications

References 10 publications

Response to 1-Year Fixed-Regimen Bevacizumab Therapy in Treatment-Naïve DME Patients: Assessment by OCT Angiography

Response to 1-Year Fixed-Regimen Bevacizumab Therapy in Treatment-Naïve DME Patients: Assessment by OCT Angiography

Romanian ophthalmologists in the renowned ophthalmic journals worldwide

Subfoveal choroidal thickness changes after intravitreal ranibizumab injections in different patterns of diabetic macular edema using a deep learning-based auto-segmentation

Contact Info

Product

Resources

About